This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Ovarian cancer	Various	<p>A microarray study suggests that an 86- gene expression profile could be useful for predicting clinical outcome of ovarian cancer patients and improving treatment regimens. In advanced ovarian tumors from 157 patients, expression of the 86 genes correlated with survival time. Patients with a high-risk expression pattern had a median survival time of 19 months compared with 41 months for those with a low-risk pattern ($p=0.0014$). Next steps include characterizing and targeting the altered pathways associated with poor survival time using human-to-mouse xenograft models.</p> <p>Oncotype DX from Genomic Health Inc. and MammaPrint from Agendia B.V. are laboratory-developed tests marketed as diagnostic adjuvants for breast cancer.</p> <p>SciBX 2(7); doi:10.1038/scibx.2009.272 Published online Feb. 19, 2009</p>	Unpatented; licensing status not applicable	<p>Crijns, A.P.G. <i>et al. PLoS Med.</i>; published online Feb. 3, 2009; doi:10.1371/journal.pmed.1000024</p> <p>Contact: Ate van der Zee, University of Groningen, Groningen, the Netherlands e-mail: a.g.j.van.der.zee@og.umcg.nl</p>